Actavis hit with suit over recalled Digitek

Maybe not faster than a speeding bullet, but close. Lawyers already are filing a class-action lawsuit against Iceland's Actavis over the recalled heart drug Digitek, which was just pulled off the market two weeks ago. (The suit also names Mylan, which distributed the meds.)

The generics maker pulled the drug because some batches may have included tablets that were twice the normal strength. Plaintiffs are alleging injury and asking for damages and medical monitoring in case of future health problems. At the time of the recall, Actavis said the stronger tablets might cause toxicity in renal-failure patients.

- see the item at the WSJ Health Blog

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.